DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Pharmacokinetic Comparison of Cilostazol SR and IR Formulations in Healthy Korean Volunteers

Information source: Severance Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Pletaal (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Severance Hospital

Summary

This study investigates safety and pharmacokinetic comparison of Pacific Pharma's PP-101 SR (test formulation) and Otsuka's PletaalŪ IR (reference formulation) for single and multiple doses and food effects on Pacific Pharma's PP-101 SR in healthy volunteers.

Clinical Details

Study design: Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Profile of Pharmacokinetics

Eligibility

Minimum age: 19 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy male or female volunteers between the ages of 19 and 55 and within 20% of

their ideal body weight, without congenital abnormality or chronic disease

- Female subjects showing positive results on a serum pregnancy test before the study,

and those who were of childbearing potential agreed to use one of the following medically accepted methods of contraception during the entire period of the study: abstinence, documented tubal ligation at least 1 year before enrollment in the study, documented placement of an intrauterine device with a proven failure rate of <1% per year, or double barrier methods (a spermicide plus a male condom or female diaphragm). Exclusion Criteria:

- History of cardiovascular, pulmonary, renal, endogenous, gastrointestinal,

hematologic, neurologic or hemorrhagic disease;

- Clinically significant findings on routine laboratory (hematology, serum chemistry

and urinalysis) or ECG tests;

- Use of prescription drugs in the 14 days immediately prior to starting the study that

had the potential to interact with the study medication;

- Use of any substance that could induce CYP3A4 synthesis (eg, St. John's wort, other

herbal medications).

Locations and Contacts

Severance Hospital, Seoul 120-752, Korea, Republic of
Additional Information

Starting date: February 2009
Last updated: October 18, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017